MedTrace Logo

Effects of Citalopram on Hostility and CHD Risk

NCT00217828 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2014-06-11

No results posted yet for this study

Summary

To evaluate the therapeutic effects of the serotonergic agent, citalopram, on hostility and other behavioral risk factors, and biological markers of disease risk (serum lipids, insulin and glucose; autonomic balance and stress-related cardiovascular reactivity; platelet activation).

Conditions

Interventions

DRUG

citalopram

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Thomas Kamarck (subproject PI) · University of Pittsburgh

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31
Primary Completion
2003-02-28
Completion
2003-02-28

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00217828 on ClinicalTrials.gov